MURRAY HILL, N.J.--(BUSINESS WIRE)--Oct. 1, 2004--C. R. Bard, Inc. (NYSE-BCR) today announced that it has completed the previously announced transaction to sell certain assets of its Endoscopic Technologies division to Conmed Corporation (NASDAQ-CNMD), for $80 million, subject to post-closing adjustment.

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, N.J., is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Please refer to our June 30, 2004 10-Q for a statement with regard to forward-looking statements, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied.

    CONTACT: C. R. Bard, Inc.
             Investor Relations:
             Eric J. Shick, 908-277-8413
             or
             Media Relations:
             Holly P. Glass, 703-754-2848

    SOURCE: C. R. Bard, Inc.